Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Seattle Children's Hospital · University of Washington · +9 more institutions
Abstract
Abstract Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) for children with recurrent or refractory CNS tumors and DIPG. Here we report results from Arm C, restricted to patients with DIPG. The primary objectives were to assess feasibility and tolerability, which were both met. Secondary objectives included assessments of CAR T cell distribution and survival. A total of 23…
Citation impact
- FWCI
- 93.45
- Percentile
- 100%
- References
- 37
Authors
42- NANicholas A. VitanzaCorresponding
Seattle Children's Hospital, University of Washington, Seattle Children's Hospital, Center for Cancer and Blood Disorders
- RRRebecca Ronsley
Seattle Children's Hospital, University of Washington
- MCMichelle Choe
Seattle Children's Hospital, University of Washington
- KSKristy Seidel
- WHWenjun Huang
Topics & keywords
- Medicine
- Regimen
- Tolerability
- Adverse effect
- Refractory (planetary science)
- Single Center
- Internal medicine
- Oncology
- Good health and well-being